NASDAQ: RENB - Renovaro Biosciences Inc.

半年間の収益性: -40.83%
セクタ: Healthcare

プロモーションスケジュール Renovaro Biosciences Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について

Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV.

さらに詳しく
It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2015-02-02
ISIN US29350E1047
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.renovarobio.com
Цена ао 2.92
1日あたりの価格変動: +1.17% (0.9065)
週ごとの価格変動: -44.08% (1.64)
月ごとの料金変更: +50.27% (0.6103)
3ヶ月間の価格変動: +86.02% (0.493)
半年間の価格変動: -40.83% (1.55)
年間の価格変動: -71.07% (3.17)
3年間の価格推移: -91.04% (10.23)
5年間の価格推移: -84.69% (5.99)
10年間の価格推移: 0% (0.9171)
年初からの価格変動: -11.82% (1.04)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 0 0
P/BV 1.17 9
P/E 0 0
EV/EBITDA -1.99 0
合計: 3.13

効率

名前 意味 学年
ROA, % -72.84 0
ROE, % -90.37 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0476 10
合計: 9

成長の衝動

名前 意味 学年
収益性 Revenue, % 42.56 6
収益性 Ebitda, % 609.97 10
収益性 EPS, % 241.32 10
合計: 7.4
さらに詳しく

機関 音量 共有, %
Vanguard Group Inc 390107 1.01
Morgan Stanley 362978 0.94
Geode Capital Management, LLC 362409 0.93
Blackrock Inc. 304656 0.79
Millennium Management LLC 126314 0.33
Susquehanna International Group, LLP 119459 0.31
State Street Corporation 97687 0.25
Northern Trust Corporation 88101 0.23
683 Capital Management LLC 73706 0.19
Qube Research & Technologies Ltd 67978 0.18

ETF 共有, % 年間の利益率, % 配当金, %
iShares Micro-Cap ETF 0.00641 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00112 38.04 0.6026
ProShares UltraPro Russell2000 0.00055 89.82 1.47873
ProShares Hedge Replication ETF 0.00016 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



スーパーバイザー 役職 支払い 生年
Dr. Francois Binette M.Sc., Ph.D. COO and Executive VP for Research & Development 504.38k 1964 (61 年)
Dr. Serhat Gümrükcü Co-Founder & Inventor N/A
Mr. Greg Duczynski Ph.D. Senior Vice President for Clinical Operations N/A
Hon. Mark R. Dybul M.D. CEO, Director & Member of HBV Scientific Advisory Board 764.58k 1963 (62 年)
Mr. Simon Tarsh Interim Chief Financial Officer N/A 1961 (64 年)

住所: United States, Los Angeles. CA, 2080 Century Park East - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.renovarobio.com